Clinical trials · California
Recurrent Oral Cavity Squamous Cell Carcinoma clinical trials in California
We’re tracking 23 recruiting recurrent oral cavity squamous cell carcinoma studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Beverly Hills, CaliforniaAges 18 years+ - NCT06769698RecruitingPhase 2
Testing fianlimab with cemiplimab for head and neck cancer
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
Los Angeles, CaliforniaAges 18 years+ - NCT06129864RecruitingPhase 3
Study of Volrustomig for advanced head and neck cancer after chemoradiation
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
Fountain Valley, CaliforniaAges 18–130 - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Palo Alto, CaliforniaAges 18 years+ - NCT06589804RecruitingPhase 3
Testing cetuximab plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
Marysville, CaliforniaAges 18 years+ - NCT06980038RecruitingPhase 2
Testing two immunotherapy drugs before surgery for advanced head and neck cancer
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
Irvine, CaliforniaAges 18 years+ - NCT07219212RecruitingPhase 1
New drug with chemo and radiation for advanced head and neck cancer
This study tests if adding an investigational drug called JNJ-90301900 to standard chemotherapy and radiation therapy works better for people with certain advanced head and neck cancers (like mouth, throat, and voice box) that have not spread to other parts of the body.
Duarte, CaliforniaAges 18–74 - NCT07195734RecruitingPhase 2
Adding chemo or immunotherapy before surgery for advanced head and neck cancer
This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
La Jolla, CaliforniaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04671667RecruitingPhase 2
Pembrolizumab vs chemo-radiation after surgery for recurrent head/neck cancer
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Anaheim, CaliforniaAges 18–79 - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Redwood City, CaliforniaAges 18 years+ - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Los Angeles, CaliforniaAges 18 years+ - NCT06736379RecruitingPhase 1
RNA Therapy Injections for Head and Neck Cancer
This trial tests a new type of immunotherapy made of self-amplifying RNA (saRNA) that produces a protein called IL-12. It's injected directly into head and neck tumors to help your immune system fight the cancer. The study is for people whose cancer has not responded well to standard treatments or who are having surgery to remove their tumor.
Stanford, CaliforniaAges 18 years+ - NCT02734537RecruitingPhase 2
Radiation with or without cisplatin after head and neck surgery
This trial studies whether adding cisplatin (a chemotherapy medicine) to radiation therapy helps people with stage III–IVA squamous cell cancer of the head and neck after they’ve had surgery. It’s meant to lower the risk of the cancer coming back.
Arroyo Grande, CaliforniaAges 18 years+ - NCT06118086RecruitingPhase 1/Phase 2
Study of REM-422 for advanced adenoid cystic carcinoma
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT07062354Enrolling by invitationPhase 2
Study of amivantamab plus chemo for head and neck cancer
This trial tests a new drug (amivantamab) combined with two chemotherapy drugs (carboplatin and paclitaxel) for people with head and neck cancer that has spread or come back after treatment and cannot be removed by surgery. This study aims to see if this combination can help shrink tumors.
Irvine, CaliforniaAges 18 years+ - NCT04892173RecruitingPhase 3
Radiation plus a tumor injection, with or without cetuximab
This trial studies whether adding a special drug given directly into a head-and-neck tumor during radiation can improve outcomes. It also looks at whether cetuximab (an antibody medicine) should be added for people who cannot or should not have certain standard chemotherapy.
Duarte, CaliforniaAges 60 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT06525220RecruitingPhase 3
New drug combo vs. standard for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
Palo Alto, CaliforniaAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Stanford, CaliforniaAges 18 years+ - NCT06710288RecruitingPhase 2
Immune cell therapy plus chemo for platinum-resistant ovarian cancer
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
El Segundo, CaliforniaAges 18–85
Where these studies are running in California
Institutions with a site for the recruiting recurrent oral cavity squamous cell carcinoma studies listed above.
- University of California, Irvine Medical Center / UC Irvine Health · 5 studies
- UC Irvine Health · 4 studies
- UC San Diego Moores Cancer Center · 4 studies
- University of California San Diego Health · 4 studies
- City of Hope Comprehensive Cancer Center · 3 studies
- Hoag Memorial Hospital Presbyterian · 3 studies
- University of California, Los Angeles (UCLA) · 3 studies
- USC / Norris Comprehensive Cancer Center · 3 studies
What taking part in a recurrent oral cavity squamous cell carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Recurrent Oral Cavity Squamous Cell Carcinoma trials in other states
Common questions
- Are there recurrent oral cavity squamous cell carcinoma clinical trials in California?
- Yes. We're currently tracking 23 recruiting recurrent oral cavity squamous cell carcinoma studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a recurrent oral cavity squamous cell carcinoma study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a recurrent oral cavity squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New recurrent oral cavity squamous cell carcinoma studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.